<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831882</url>
  </required_header>
  <id_info>
    <org_study_id>26529</org_study_id>
    <nct_id>NCT01831882</nct_id>
  </id_info>
  <brief_title>Identifying Biological Markers for Severe Depression</brief_title>
  <official_title>Identifying Biological Markers for Severe Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pritzker Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the biological components of major&#xD;
      depression. The investigators are particularity interested in genetic variation and how it&#xD;
      contributes to cortisol (because cortisol is higher in severe depression than mild depression&#xD;
      or healthy controls) and how it contributes to clinical symptoms, especially suicidal&#xD;
      ideation/behavior and psychosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Actual">August 2020</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetics</measure>
    <time_frame>1 year</time_frame>
    <description>Blood will be drawn for gene expression, which includes genetics and metallothionein assessments. Blood will also be drawn for later assay of immune function/measures and neurotophins, and for future studies.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Physiologic</measure>
    <time_frame>1 year</time_frame>
    <description>Cortisol hormone levels will be measured in blood (suppression test), hair and saliva samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurocognition</measure>
    <time_frame>1 year</time_frame>
    <description>Standardized neuropsychological measures will be used to assess neurocognition including, tests involving verbal learning, visual reproduction, attentional flexibility, and memory.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical</measure>
    <time_frame>1 year</time_frame>
    <description>Clinical psychiatric measures will be used to assess depression (HAM-D), psychotic features, suicidality, childhood trauma, and anhedonia.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">210</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Major Depressive Disorder</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We will be retaining biospecimens including, whole blood, serum, hair and saliva tissues&#xD;
      samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatient hospitals, outpatient clinics, community.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria for depressed patients:&#xD;
&#xD;
          1. Diagnostic and Statistical Manual of Mental Disorders 4th Edition (DSM-IV) diagnosis&#xD;
             of Unipolar Major Depressive Disorder with or without psychotic features.&#xD;
&#xD;
          2. 21-item Hamilton Depression Rating Scale (HDRS) score greater than or equal to 21.&#xD;
&#xD;
          3. Thase Core Endogenomorphic Scale score greater than or equal to 8 on the items&#xD;
             included in the 21-item HDRS.&#xD;
&#xD;
          4. Between 18 - 70 years of age.&#xD;
&#xD;
          5. If currently taking antipsychotic, antidepressant, anticonvulsant, and/or&#xD;
             mood-stabilizing medications, must be stable on the medication for at least one-week&#xD;
             prior to entering the study.&#xD;
&#xD;
          6. Pre-existing (current) primary treating psychiatrist for subjects with psychotic&#xD;
             features.&#xD;
&#xD;
          7. Any secondary diagnoses from the anxiety disorder spectrum is acceptable. Primary&#xD;
             pre-existing chronic Obsessive-Compulsive Disorder (OCD) will be an exclusion&#xD;
             criteria.&#xD;
&#xD;
        Inclusion criteria for healthy controls:&#xD;
&#xD;
          1. Between 18 - 70 years of age.&#xD;
&#xD;
          2. Have a HAM-D score of less than or equal to 5.&#xD;
&#xD;
        Exclusion Criteria for depressed patients:&#xD;
&#xD;
          1. Electroconvulsive Therapy (ECT) in the 6 months prior to the study.&#xD;
&#xD;
          2. Abuse of drugs or alcohol in the 6 months prior to study.&#xD;
&#xD;
          3. Unstable or untreated hypertension or cardiovascular disease.&#xD;
&#xD;
          4. Use of additional prescription medications, street drugs, or alcohol during the week&#xD;
             before the study.&#xD;
&#xD;
          5. Any Axis II diagnosis or traits which would make participation in the study difficult.&#xD;
&#xD;
          6. Current pregnancy or lactation.&#xD;
&#xD;
          7. Post-partum depression&#xD;
&#xD;
          8. Diagnosis of obsessive-compulsive disorder&#xD;
&#xD;
          9. History of significant cognitive decline&#xD;
&#xD;
        Exclusion criteria for healthy controls:&#xD;
&#xD;
          1. Personal history of Axis I or Axis II disorders.&#xD;
&#xD;
          2. Active unstable medical problems.&#xD;
&#xD;
          3. Abuse of drugs or alcohol in the 6 months prior to study.&#xD;
&#xD;
          4. Use of additional prescription medications, street drugs, or alcohol during the week&#xD;
             before the study.&#xD;
&#xD;
          5. Currently pregnant or lactating.&#xD;
&#xD;
          6. History of significant cognitive decline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Schatzberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University, Department of Psychiatry and Behavioral Sciences</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 9, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Alan Schatzberg</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

